Compare Stocks: BMEA, RCKT, ARCT, and UPB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$15.19 -6.1%	$7.89	$5.50 ▼ $24.17	$459.60M	2.39	1.33 million shs	1.62 million shs
BMEA Biomea Fusion	$1.73 +3.0%	$1.33	$0.87 ▼ $2.99	$121.77M	-0.28	1.49 million shs	1.17 million shs
RCKT Rocket Pharmaceuticals	$3.86 +6.6%	$3.51	$2.53 ▼ $5.45	$397.38M	0.47	1.49 million shs	3.45 million shs
UPB Upstream Bio	$6.69 -1.5%	$6.95	$5.85 ▼ $33.68	$371.89M	1.26	618,866 shs	445,475 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+2.15%	+47.13%	+181.22%	+104.17%	-6.48%
BMEA Biomea Fusion	-1.75%	+23.53%	+34.40%	+21.74%	-9.68%
RCKT Rocket Pharmaceuticals	-1.09%	+4.02%	+15.29%	+17.92%	+9.04%
UPB Upstream Bio	-4.77%	-0.88%	+6.09%	-18.78%	-59.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$15.19 -6.1%	$7.89	$5.50 ▼ $24.17	$459.60M	2.39	1.33 million shs	1.62 million shs
BMEA Biomea Fusion	$1.73 +3.0%	$1.33	$0.87 ▼ $2.99	$121.77M	-0.28	1.49 million shs	1.17 million shs
RCKT Rocket Pharmaceuticals	$3.86 +6.6%	$3.51	$2.53 ▼ $5.45	$397.38M	0.47	1.49 million shs	3.45 million shs
UPB Upstream Bio	$6.69 -1.5%	$6.95	$5.85 ▼ $33.68	$371.89M	1.26	618,866 shs	445,475 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+2.15%	+47.13%	+181.22%	+104.17%	-6.48%
BMEA Biomea Fusion	-1.75%	+23.53%	+34.40%	+21.74%	-9.68%
RCKT Rocket Pharmaceuticals	-1.09%	+4.02%	+15.29%	+17.92%	+9.04%
UPB Upstream Bio	-4.77%	-0.88%	+6.09%	-18.78%	-59.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.60	Moderate Buy	$20.00	30.12% Upside
BMEA Biomea Fusion	2.67	Moderate Buy	$9.00	430.97% Upside
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.57	117.55% Upside
UPB Upstream Bio	2.43	Hold	$29.67	339.51% Upside

Current Analyst Ratings Breakdown

Latest BMEA, RCKT, ARCT, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/11/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/11/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/3/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$18.72M	23.33	N/A	N/A	$6.04 per share	2.54
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.17 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.36 per share	N/A
UPB Upstream Bio	$3.16M	117.07	N/A	N/A	$4.95 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
BMEA Biomea Fusion	-$61.80M	-$0.29	N/A	N/A	N/A	N/A	-253.73%	-97.91%	11/3/2026 (Estimated)
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest BMEA, RCKT, ARCT, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/6/2026	Q2 2026	BMEA Biomea Fusion	-$0.2235	-$0.12	+$0.1035	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	4.65%	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
BMEA Biomea Fusion	N/A	3.47	3.47
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
BMEA Biomea Fusion	96.72%
RCKT Rocket Pharmaceuticals	98.39%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
BMEA Biomea Fusion	10.60%
RCKT Rocket Pharmaceuticals	21.30%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
BMEA Biomea Fusion	50	72.48 million	64.80 million	Optionable
RCKT Rocket Pharmaceuticals	240	109.78 million	86.39 million	Optionable
UPB Upstream Bio	38	54.77 million	45.76 million	N/A

BMEA, RCKT, ARCT, and UPB Headlines

Recent News About These Companies

Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

August 25 at 6:40 AM | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by Analysts

August 25 at 4:13 AM | marketbeat.com

Upstream Bio (NASDAQ:UPB) Price Target Raised to $9.00

August 17, 2026 | americanbankingnews.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

August 14, 2026 | marketbeat.com

Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright

August 14, 2026 | marketbeat.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

August 11, 2026 | marketbeat.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB

August 6, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts

July 31, 2026 | marketbeat.com

Upstream Bio (UPB) Expected to Release Quarterly Earnings on Wednesday

July 29, 2026 | marketbeat.com

Altshuler Shaham Ltd Reduces Position in Upstream Bio, Inc. $UPB

July 29, 2026 | marketbeat.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

July 14, 2026 | zacks.com

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

June 25, 2026 | insidermonkey.com

10 small-cap U.S. healthcare stocks with the weakest momentum grades

June 24, 2026 | seekingalpha.com

Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?

June 23, 2026 | insidermonkey.com

Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients

June 19, 2026 | businesswire.com

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the ...

June 14, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, RCKT, ARCT, and UPB Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$15.19 -0.98 (-6.06%)

As of 04:00 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Biomea Fusion NASDAQ:BMEA

$1.73 +0.05 (+2.98%)

As of 04:00 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.86 +0.24 (+6.63%)

As of 04:00 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Upstream Bio NASDAQ:UPB

$6.69 -0.10 (-1.47%)

As of 04:00 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMEA, RCKT, ARCT, and UPB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMEA, RCKT, ARCT, and UPB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMEA, RCKT, ARCT, and UPB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, RCKT, ARCT, and UPB Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Biomea Fusion NASDAQ:BMEA

Rocket Pharmaceuticals NASDAQ:RCKT

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMEA, RCKT, ARCT, and UPB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMEA, RCKT, ARCT, and UPB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMEA, RCKT, ARCT, and UPB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, RCKT, ARCT, and UPB Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Biomea Fusion NASDAQ:BMEA

Rocket Pharmaceuticals NASDAQ:RCKT

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools